Literature DB >> 26899451

Mechanism of action of brexpiprazole: comparison with aripiprazole.

Stephen M Stahl.   

Abstract

Brexpiprazole is a new therapeutic agent that was recently approved for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder. Brexpiprazole has features that both overlap and contrast with a related molecule, aripiprazole, and these features are discussed here.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26899451     DOI： 10.1017/S1092852915000954

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  12 in total

Review 1.  Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.

Authors:  Jean-Michel Azorin; Nicolas Simon
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

Review 2.  Brexpiprazole: A Review in Schizophrenia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

3.  Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.

Authors:  Min Ma; Qian Ren; Yuko Fujita; Chun Yang; Chao Dong; Yuta Ohgi; Takashi Futamura; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2017-07-26       Impact factor: 4.530

4.  Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems.

Authors:  Kouji Fukuyama; Eishi Motomura; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

5.  Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.

Authors:  De-Juan Li; Qin Yue; Lu Liu; Ke-Ke Che; Xue-Mei Liu; Chang-Hua Hu
Journal:  Acta Pharmacol Sin       Date:  2021-05-11       Impact factor: 7.169

6.  Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling.

Authors:  Min Ma; Qian Ren; Chun Yang; Ji-Chun Zhang; Wei Yao; Chao Dong; Yuta Ohgi; Takashi Futamura; Kenji Hashimoto
Journal:  Sci Rep       Date:  2016-12-19       Impact factor: 4.379

7.  Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation.

Authors:  Min Ma; Qian Ren; Chun Yang; Ji-Chun Zhang; Wei Yao; Chao Dong; Yuta Ohgi; Takashi Futamura; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2016-11-15       Impact factor: 4.530

Review 8.  Clinical role of brexpiprazole in depression and schizophrenia.

Authors:  Nishant B Parikh; Diana M Robinson; Anita H Clayton
Journal:  Ther Clin Risk Manag       Date:  2017-03-10       Impact factor: 2.423

9.  Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile.

Authors:  Jacek Stefanowicz; Tomasz Słowiński; Martyna Z Wróbel; Grzegorz Ślifirski; Maciej Dawidowski; Zdzisława Stefanowicz; Magdalena Jastrzębska-Więsek; Anna Partyka; Anna Wesołowska; Jadwiga Turło
Journal:  Med Chem Res       Date:  2018-06-22       Impact factor: 1.965

Review 10.  Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.

Authors:  Amber N Edinoff; Natalie W Wu; Benjamin S Maxey; Amy L Ren; Kenna N Leethy; Brook Girma; Amira Odisho; Jessica S Kaye; Aaron J Kaye; Adam M Kaye; Alan D Kaye; George Mychaskiw; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.